Loading
Recursion Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Mubadala Investment Co PJSC, was filed 03 Mar 2023.
Recursion Pharmaceuticals, Inc.: what insiders have been doing
This page follows insider dealings at Recursion Pharmaceuticals, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Salt Lake City, United States. The group dates from 2013. 14 insiders have disclosed 93 filings since 20 October 2025.
There is no open-market purchase to report; the filings show 14 sales worth €4.2M by 5 insiders. Borgeson Blake filed the largest sale, €828k, on 4 December 2025.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
With 93 filings in twelve months, the company is more active than the median of 22 filings across the 5,453 companies we follow on the same exchange. Our records for Recursion Pharmaceuticals, Inc. go back to 2021, with 17 purchases and 77 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 74.7 m USD and net income of -644.8 m USD.
In the same sector, recent insider purchases at Vivos Inc and Anixa Biosciences Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
483
Thresholds
n/a
Buy Volume
€6M
17 ops. · all time
Sell Volume
€11M
77 ops. · all time
Who traded when
BuySaleBorgeson Blake7 sales
Gibson Christopher4 sales
Najat Khan3 sales
Ben R. Taylor1 sale
Bumpus Namandje1 sale
Since the insiders bought
- +49.8%Entry US$8.21 · Close at T+365 US$12.30
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Recursion Pharmaceuticals, Inc. Buy (bullish), based on 6 analysts. Average price target: US$7.32.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 25,993 of 26,261 companies
7.1
score / 100
Value9
Quality6
FCF yld-20%
Earn yld-35%
EV/EBITDA·
ROE-57%
Gross mgn4.4%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.47
Analyst consensus
6 analystsBuy
US$4.00Target US$7.32(+111%)US$10.00
Income statement
RevenueUS$74.3M
Gross profitUS$3.3M4% margin
EBITDA-US$559.4M-753% margin
Net income-US$644.8M-868.3% margin
Valuation
PER (forward)-4.0x
P/Book2.0x
Beta1.03
Balance sheet & cash
Market capUS$1.9B
Total debtUS$78M
Free Cash Flow-US$380.4M
Debt / Equity7%
Profitability & ownership
ROE-56.6%
ROA-27.3%
% insiders1.8%
% institutions64.4%
Last declaration on 7 October 2026
Declarations483 total
25,000 shares@ US$2.220.0022% mcap18.2% of flowClass A Common StockSEC:0001601830-26-000119:0
50,000 shares@ US$4.840.0095% mcap2.5% of flowClass ASEC144:0001959173-26-007282
25,000 shares@ US$5.000.0049% mcap100.0% of flowClass ASEC144:0001959173-26-007281
3,378 shares0Class A Common StockSEC:0001601830-26-000115:0
4,607 shares0Class A Common StockSEC:0001601830-26-000116:0
5,396 shares@ US$3.410.0009% mcap1.7% of flowClass A Common StockSEC:0001601830-26-000110:0
22,408 shares@ US$3.51760.0038% mcap6.9% of flowClass A Common StockSEC:0001601830-26-000105:0
22,408 shares@ US$3.51760.0038% mcap48.2% of flowCommonSEC144:0001628280-26-060859
77,290 shares@ US$3.390.013% mcap1.6% of flowClass ASEC144:0001959173-26-006306
75,000 shares@ US$3.400.012% mcap1.5% of flowClass ASEC144:0001959173-26-006256
100,000 shares@ US$3.2750.016% mcap2.0% of flowClass ASEC144:0001959173-26-006204
26,806 shares@ US$2.99930.0039% mcap0.5% of flowClass ASEC144:0001959173-26-006192
25,018 shares@ US$3.160.0039% mcap7.2% of flowClass A Common StockSEC:0001712276-26-000009:0
80,498 shares@ US$3.160.012% mcap22.5% of flowClass A Common StockSEC:0002020969-26-000006:0
26,657 shares@ US$3.160.0041% mcap67.5% of flowClass A Common StockSEC:0002006495-26-000012:0
100,000 shares@ US$3.310.016% mcap2.0% of flowClass ASEC144:0001959173-26-005979
50,000 shares@ US$3.370.0083% mcap1.0% of flowClass ASEC144:0001959173-26-005928
100,000 shares@ US$3.26750.016% mcap2.0% of flowClass ASEC144:0001959173-26-005848
100,000 shares@ US$3.25410.016% mcap2.0% of flowClass ASEC144:0001959173-26-005744
30,000 shares@ US$3.250.0048% mcap1.0% of flowClass ASEC144:0001959173-26-005593
75,000 shares@ US$3.2650.012% mcap1.5% of flowClass ASEC144:0001959173-26-005577
75,000 shares@ US$3.000.011% mcap1.4% of flowClass ASEC144:0001959173-26-005467
50,000 shares@ US$3.02740.0075% mcap0.9% of flowClass ASEC144:0001959173-26-005445
50,000 shares@ US$3.05410.0076% mcap0.9% of flowClass ASEC144:0001959173-26-005384
100,000 shares@ US$3.04260.015% mcap1.8% of flowClass ASEC144:0001959173-26-005307
25 of 483 declarations
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (ticker RXRX) is a U.S.-based biotechnology company listed on the NASDAQ in the United States, with a business model that sits at the intersection of healthcare, chemistry, and artificial intelligence. Founded in 2013, the company was built around a clear thesis: industrialize drug discovery by combining biology, automation, large-scale data generation, and advanced computing. Its corporate headquarters are in Salt Lake City, Utah, and its operating footprint extends beyond the U.S. to the United Kingdom and multiple North American talent hubs, underscoring a more international operating profile. ([recursion.com](https://www.recursion.com/our-story?utm_source=openai))
The company’s core asset is Recursion OS, a proprietary end-to-end discovery and development platform that links biological and chemical data generation with machine learning, software engineering, and experimental execution. This platform supports both the internal pipeline and selective partnerships with major pharmaceutical and technology companies. Recursion focuses on areas with substantial unmet medical need, including oncology, rare disease, neuroscience, and immunology/inflammation. The company describes itself as a “clinical stage TechBio” company, which captures its hybrid identity as both a biotech developer and a technology platform provider. ([ir.recursion.com](https://ir.recursion.com/investor-relations?utm_source=openai))
Read moreShow less
From a competitive standpoint, Recursion stands out less for a marketed product and more for a differentiated R&D engine aimed at improving speed, scale, and productivity in drug discovery. Its edge comes from generating proprietary datasets and using them to improve target selection, molecule optimization, and program prioritization. The company is pursuing potentially first-in-class and best-in-class assets while also monetizing parts of the platform through collaborations. In an industry defined by high attrition, this approach is intended to shorten timelines and lower discovery costs. ([fintel.io](https://fintel.io/doc/sec-recursion-pharmaceuticals-inc-1601830-10k-2025-february-28-20147-8813?utm_source=openai))
A major recent milestone was the completion of the combination with Exscientia in November 2024, creating a more integrated AI-driven drug discovery platform. Management stated that the combined portfolio included more than 10 clinical and preclinical programs, more than 10 advanced discovery programs, and additional partnered programs. During 2025, Recursion also reported progress in its Sanofi collaboration and announced the acquisition of Rallybio’s remaining interest in an ENPP1 program, reinforcing a strategy centered on partnership expansion, portfolio deepening, and value creation through platform leverage. ([ir.recursion.com](https://ir.recursion.com/news-releases/news-release-details/recursion-and-exscientia-two-leaders-ai-drug-discovery-space?t=&utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
